DK2799090T3 - Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering - Google Patents
Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering Download PDFInfo
- Publication number
- DK2799090T3 DK2799090T3 DK14165008.5T DK14165008T DK2799090T3 DK 2799090 T3 DK2799090 T3 DK 2799090T3 DK 14165008 T DK14165008 T DK 14165008T DK 2799090 T3 DK2799090 T3 DK 2799090T3
- Authority
- DK
- Denmark
- Prior art keywords
- free
- chelate
- lanthanide
- macrocyclic chelate
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (10)
1. Fremgangsmåde til fremstilling af en flydende farmaceutisk formulering, hvilken formulering indeholder et kompleks af makrocyklisk chelat med et lanthanid og en mol/mol-mængde af frit makrocyklisk chelat på mellem 0,002% og 0,4%, hvilken fremgangsmåde omfatter følgende successive trin: b) fremstilling af en flydende farmaceutisk sammensætning, hvilken sammensætning indeholder komplekset af makrocyklisk chelat med et lanthanid, frit makrocyklisk chelat, der ikke forefindes i form af en excipiens X[X',L] hvor L er det makrocykliske chelat, og X og X' er en metalion, navnlig valgt uafhængigt blandt calcium, natrium, zink og magnesium og/eller frit lanthanid, hvilket trin b) består af fremstilling af et fast kompleks [chelat-lanthanid] og afopløsning af komplekset i vand; c) måling i den farmaceutiske formulering opnået i trin b) af koncentrationen af frit makrocyklisk chelat Cch i og/eller af frit lanthanid Cian i; d) justering af CCh i og/eller af Cian i ved tilsætning til formuleringen opnået i trin b): - hvis Cian i > 0 og/eller CCh i < Ct Ch i, af frit makrocyklisk chelat, - hvis Cian i = 0 og CCh i > Ct ch i, af frit lanthanid, til opnåelse af CCh i = Ct ch i og Cian i = 0, hvor Ct Ch i er målkoncentrationen af det frie makrocykliske chelat i den endelige flydende farmaceutiske formulering, idet Ct Ch i er udvalgt i intervallet mellem 0,002 % og 0,4 % mol/mol, hvor mængden af frit makrocyklisk chelat i den endelige flydende farmaceutiske formulering svarer til andelen af frit makrocyklisk chelat i forhold til mængden af kompleksbundet makrocyklisk chelat DOTA-Gd i den endelige flydende farmaceutiske formulering i mol/mol, og hvor det makrocykliske chelat er DOTA, og lanthanid er gadolinium.
2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at mol/mol- mængden af frit makrocyklisk chelat er på mellem 0,025% og 0,25%.
3. Fremgangsmåde ifølge et hvilket som helst af kravene 1 eller 2, kendetegnet ved, at den farmaceutiske formulering er en farmaceutisk formulering af megluminsaltet af et DOTA-gadolinium-kompleks.
4. Fremgangsmåde ifølge krav 3, kendetegnet ved, at justeringstrinet d) til sidst omfatter et trin med justering af pH-værdien og volumenet, med meglumin.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1-4, kendetegnet ved, at mængden af calcium i den flydende farmaceutiske formulering, der skal administreres til patienten, er mindre end 50 ppm, fordelagtigt mindre end 20 ppm, mere fordelagtigt mindre end 5 ppm.
6. Fremgangsmåde ifølge krav 5, kendetegnet ved, at mængden af calcium i den flydende farmaceutiske formulering, der skal administreres til patienten, er mindre end 50 ppm, og ved, at mængden af calcium i bestanddelene, der er anvendt til den farmaceutiske opløsning i trin b) , nemlig DOTA-pulveret, vand og meglumin, er mindre end 50 ppm, fordelagtigt mindre end 20 ppm.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 5 eller 6, kendetegnet ved, at den inden trin c) omfatter et mellemliggende trin b2) til måling af mængden af calcium og, når det er relevant, til fjernelse af det overskydende calcium.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, kendetegnet ved, at den omfatter et yderligere trin e) til kontrol af CGh i og C lan 1 ·
9. Fremgangsmåde ifølge krav 1, kendetegnet ved, at fremstillingen af det faste kompleks inddrager mindst ét behandlingstrin udvalgt blandt filtrering, opkoncentrering, krystallisation, tørring og sprøjtning til opnåelse af de passende fysisk-kemiske egenskaber med hensyn til opløselighed og renhed.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, kendetegnet ved, at trin c) udføres ved pH 7.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0851055A FR2927539B1 (fr) | 2008-02-19 | 2008-02-19 | Procede de preparation d'une formulation pharmaceutique d'agents de contraste. |
EP08154745 | 2008-04-17 | ||
US12/155,997 US20090208421A1 (en) | 2008-02-19 | 2008-06-12 | Process for preparing a pharmaceutical formulation of contrast agents |
EP13154448.8A EP2591807A1 (en) | 2008-02-19 | 2009-02-18 | Process for preparing a pharmaceutical formulation of contrast agents |
Publications (3)
Publication Number | Publication Date |
---|---|
DK2799090T3 true DK2799090T3 (da) | 2016-10-03 |
DK2799090T5 DK2799090T5 (da) | 2017-04-18 |
DK2799090T4 DK2799090T4 (da) | 2020-05-18 |
Family
ID=40955314
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09712403.6T DK2242515T3 (da) | 2008-02-19 | 2009-02-18 | Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering |
DK14165008.5T DK2799090T4 (da) | 2008-02-19 | 2009-02-18 | Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering |
DK14165006.9T DK2799089T3 (da) | 2008-02-19 | 2009-02-18 | Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09712403.6T DK2242515T3 (da) | 2008-02-19 | 2009-02-18 | Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14165006.9T DK2799089T3 (da) | 2008-02-19 | 2009-02-18 | Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering |
Country Status (17)
Country | Link |
---|---|
US (6) | US20090208421A1 (da) |
EP (6) | EP2799089B9 (da) |
JP (3) | JP5469615B2 (da) |
KR (1) | KR101063060B1 (da) |
CN (1) | CN101977633B (da) |
BR (1) | BRPI0908221B1 (da) |
CA (1) | CA2714118C (da) |
CY (2) | CY1115259T1 (da) |
DE (1) | DE202008010019U1 (da) |
DK (3) | DK2242515T3 (da) |
ES (3) | ES2593127T5 (da) |
HR (2) | HRP20140537T1 (da) |
HU (2) | HUE031091T2 (da) |
LT (2) | LT2799089T (da) |
PL (3) | PL2242515T3 (da) |
PT (3) | PT2799089T (da) |
WO (1) | WO2009103744A2 (da) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090208421A1 (en) * | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
FR2945448B1 (fr) | 2009-05-13 | 2012-08-31 | Guerbet Sa | Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre. |
EP2338874A1 (en) * | 2009-12-16 | 2011-06-29 | Bracco Imaging S.p.A | Process for the preparation of chelated compounds |
CN105025854A (zh) * | 2013-01-07 | 2015-11-04 | 宾夕法尼亚大学董事会 | 治疗皮肤t细胞淋巴瘤的组合物和方法 |
TW201514188A (zh) * | 2013-03-13 | 2015-04-16 | Lantheus Medical Imaging Inc | 製備釓磷維塞三鈉單水合物之方法 |
EP2786768A1 (en) * | 2013-04-04 | 2014-10-08 | Agfa Healthcare | Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide |
CN116173247A (zh) * | 2013-04-26 | 2023-05-30 | 法国加柏公司 | 造影剂配制品与有关制备方法 |
KR101466602B1 (ko) * | 2013-05-31 | 2014-12-01 | 동국제약 주식회사 | 메글루민 가도테레이트를 포함하는 조영제 조성물의 제조방법 |
AT516104B1 (de) | 2014-07-31 | 2016-08-15 | Sanochemia Pharmazeutika Ag | Verfahren zum Herstellen einer flüssigen pharmazeutischen Zubereitung |
KR101646211B1 (ko) * | 2014-11-12 | 2016-08-05 | (주)디아이테크 | 자기공명영상용 조영제의 제조방법 |
GB201421161D0 (en) * | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Metal complex formulations |
GB201421163D0 (en) | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Formulations of metal complexes |
GB201421162D0 (en) * | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Lanthanide complex formulations |
US20170035461A1 (en) * | 2015-08-03 | 2017-02-09 | Jeffery Deal | Reversible tattoo colorant and method |
DE102015013939A1 (de) * | 2015-09-15 | 2017-03-16 | be imaging GmbH | Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen |
EP3183008B1 (en) * | 2015-09-30 | 2019-06-26 | Duke University | Ascorbate formulations and methods of use as contrast agents |
KR101625656B1 (ko) * | 2015-10-16 | 2016-05-30 | 최경석 | 자기공명영상용 조영제의 제조방법 |
EP3383441A1 (en) | 2015-11-30 | 2018-10-10 | GE Healthcare AS | Formulations comprising a combination of mri contrast agents |
GB201610738D0 (en) | 2016-06-20 | 2016-08-03 | Ge Healthcare As | Chelate compounds |
WO2018069176A1 (en) | 2016-10-12 | 2018-04-19 | T2Pharma Gmbh | Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates |
WO2018069179A1 (en) | 2016-10-12 | 2018-04-19 | T2Pharma Gmbh | Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates |
EP3315141B1 (de) * | 2016-10-28 | 2020-10-21 | B.E. Imaging GmbH | Verfahren zur herstellung von pharmazeutischen formulierungen enthaltend chelatkomplexe von gadolinium mit reduziertem gehalt an toxischen verunreinigungen |
RU2755181C2 (ru) | 2016-11-28 | 2021-09-14 | Байер Фарма Акциенгезельшафт | Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации |
PL3558394T3 (pl) | 2016-12-21 | 2020-11-16 | Ge Healthcare As | Oparte na tetraazabicyklo-makrocyklu związki chelatowe manganu odpowiednie jako środki do obrazowania metodą MRI |
US20190269805A1 (en) * | 2016-12-29 | 2019-09-05 | Inventure, LLC | Solvent-free gadolinium contrast agents |
WO2018125916A1 (en) * | 2016-12-29 | 2018-07-05 | Inventure, LLC | Solvent-free gadolinium contrast agents |
RU2019139432A (ru) | 2017-05-05 | 2021-06-07 | Сентр фор Проуб Девелопмент энд Коммерсиализэйшн | Фармакокинетическая оптимизация бифункциональных хелатов и их применение |
WO2018204872A2 (en) | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
WO2019020662A1 (de) * | 2017-07-27 | 2019-01-31 | Sanochemia Pharmazeutika Ag | Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen |
FR3072281B1 (fr) * | 2017-10-13 | 2020-12-04 | Nh Theraguix | Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs |
JP7332600B2 (ja) | 2017-12-20 | 2023-08-23 | ゼネラル・エレクトリック・カンパニイ | アニオン性キレート化合物 |
AT521001B1 (de) * | 2018-02-23 | 2020-10-15 | Sanochemia Pharmazeutika Ag | Herstellungsverfahren für ein Kontrastmittel |
MX2021006024A (es) | 2018-11-23 | 2021-07-06 | Bayer Ag | Formulacion de medios de contraste y proceso para prepararlos. |
US20200215198A1 (en) * | 2019-01-03 | 2020-07-09 | Ionpath, Inc. | Compositions and reagents for ion beam imaging |
FR3091873B1 (fr) * | 2019-01-17 | 2020-12-25 | Guerbet Sa | Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification |
EP4048322A1 (en) * | 2019-10-25 | 2022-08-31 | Bracco Imaging SPA | Pharmaceutical compositions of gd-based contrast agents |
GB201919073D0 (en) | 2019-12-20 | 2020-02-05 | Ge Healthcare As | Novel manufacturing process |
TWI779284B (zh) * | 2020-05-06 | 2022-10-01 | 商之器科技股份有限公司 | 用於影像資料標註的裝置 |
US20230248851A1 (en) | 2020-06-10 | 2023-08-10 | Justesa Imagen S.A.U. | Procedure for obtaining gadoterate meglumine from high-purity tetraxetan (dota) and its use in the preparation of injectable galenical formulations |
CN113801071B (zh) * | 2021-09-14 | 2023-04-07 | 安徽普利药业有限公司 | 一种钆特酸葡甲胺的精制方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
US4957939A (en) * | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
NL194579C (nl) * | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostisch middel. |
US4639365A (en) | 1984-10-18 | 1987-01-27 | The Board Of Regents, The University Of Texas System | Gadolinium chelates as NMR contrast agents |
US5082649A (en) | 1987-06-30 | 1992-01-21 | Mallinckrodt Medical, Inc. | Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions |
FR2596992B1 (fr) | 1986-04-11 | 1988-12-16 | Guerbet Sa | Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic |
DE3640708C2 (de) * | 1986-11-28 | 1995-05-18 | Schering Ag | Verbesserte metallhaltige Pharmazeutika |
US5049667A (en) | 1987-04-14 | 1991-09-17 | Guerbet S.A. | Nitrogen-containing cyclic ligands |
EP0367787B2 (en) | 1987-06-30 | 1999-01-27 | Mallinckrodt, Inc. (a Delaware corporation) | Method for enhancing the safety of metal-ligand chelates as x-ray contrast agents |
AU4317889A (en) | 1988-09-27 | 1990-05-01 | Salutar, Inc. | Chelate compositions |
JPH02173483A (ja) | 1988-12-23 | 1990-07-04 | Komatsu Ltd | 高速流量制御弁 |
US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
US4967447A (en) | 1989-09-25 | 1990-11-06 | Romaine Jeffrey L | Fish slicer and method of frying fish |
US5650133A (en) | 1990-01-19 | 1997-07-22 | Nycomed Salutar | Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality |
GB9000564D0 (en) | 1990-01-10 | 1990-03-14 | Dow Rheinmuenster | Modified polyoxyethlene epoxy resin amphiphiles and stable aqueous epoxy dispersions thereof |
GB9001245D0 (en) | 1990-01-19 | 1990-03-21 | Salutar Inc | Compounds |
CA2039399C (en) | 1990-04-25 | 2000-09-05 | C. Allen Chang | Dual functioning excipient for metal chelate contrast agents |
US7385041B2 (en) * | 1990-04-25 | 2008-06-10 | Bracco International B.V. | Dual functioning excipient for metal chelate contrast agents |
WO1993020852A2 (en) | 1992-04-13 | 1993-10-28 | The Dow Chemical Company | Macrocyclic chelating agents, chelates and conjugates thereof |
GB9318550D0 (en) | 1993-09-07 | 1993-10-20 | Nycomed Salutar Inc | Chelants |
FR2736051B3 (fr) * | 1995-06-29 | 1997-09-26 | Guerbet Sa | Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US7048907B2 (en) * | 2001-02-05 | 2006-05-23 | Biophysics Assay Laboratory, Inc. | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products |
TWI240632B (en) | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
WO2004013161A2 (en) | 2002-08-06 | 2004-02-12 | Epix Pharmaceuticals, Inc. | Peptide aggregates |
WO2007002109A2 (en) | 2005-06-20 | 2007-01-04 | The Regents Of The University Of California | Multidentate pyrone-derived chelators for medicinal imaging and chelation |
EP1940841B9 (fr) | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
WO2007106544A2 (en) | 2006-03-15 | 2007-09-20 | Mallinckrodt Inc. | Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
WO2007121453A2 (en) | 2006-04-17 | 2007-10-25 | The Regents Of The University Of California | 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents |
US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
-
2008
- 2008-06-12 US US12/155,997 patent/US20090208421A1/en not_active Abandoned
- 2008-07-25 DE DE202008010019U patent/DE202008010019U1/de not_active Withdrawn - After Issue
-
2009
- 2009-02-18 PT PT141650069T patent/PT2799089T/pt unknown
- 2009-02-18 DK DK09712403.6T patent/DK2242515T3/da active
- 2009-02-18 ES ES14165008T patent/ES2593127T5/es active Active
- 2009-02-18 PL PL09712403T patent/PL2242515T3/pl unknown
- 2009-02-18 LT LTEP14165006.9T patent/LT2799089T/lt unknown
- 2009-02-18 EP EP14165006.9A patent/EP2799089B9/en not_active Revoked
- 2009-02-18 PT PT97124036T patent/PT2242515E/pt unknown
- 2009-02-18 ES ES09712403.6T patent/ES2477541T3/es active Active
- 2009-02-18 BR BRPI0908221-2A patent/BRPI0908221B1/pt active IP Right Grant
- 2009-02-18 DK DK14165008.5T patent/DK2799090T4/da active
- 2009-02-18 EP EP19204417.0A patent/EP3620179A1/en not_active Withdrawn
- 2009-02-18 LT LTEP14165008.5T patent/LT2799090T/lt unknown
- 2009-02-18 PL PL14165006T patent/PL2799089T3/pl unknown
- 2009-02-18 EP EP13154448.8A patent/EP2591807A1/en not_active Ceased
- 2009-02-18 DK DK14165006.9T patent/DK2799089T3/da active
- 2009-02-18 ES ES14165006.9T patent/ES2597782T3/es active Active
- 2009-02-18 HU HUE14165008A patent/HUE031091T2/en unknown
- 2009-02-18 EP EP09712403.6A patent/EP2242515B9/en not_active Revoked
- 2009-02-18 PT PT141650085T patent/PT2799090T/pt unknown
- 2009-02-18 WO PCT/EP2009/051937 patent/WO2009103744A2/en active Application Filing
- 2009-02-18 HU HUE14165006A patent/HUE030219T2/en unknown
- 2009-02-18 JP JP2010547173A patent/JP5469615B2/ja active Active
- 2009-02-18 PL PL14165008.5T patent/PL2799090T5/pl unknown
- 2009-02-18 EP EP16194654.6A patent/EP3159014A1/en not_active Ceased
- 2009-02-18 EP EP14165008.5A patent/EP2799090B2/en active Active
- 2009-02-18 CA CA2714118A patent/CA2714118C/en active Active
- 2009-02-18 CN CN2009801096136A patent/CN101977633B/zh active Active
- 2009-02-18 US US12/918,259 patent/US9655983B2/en active Active
- 2009-02-18 KR KR1020107020477A patent/KR101063060B1/ko active IP Right Review Request
-
2013
- 2013-08-20 US US13/971,672 patent/US20130336898A1/en not_active Abandoned
-
2014
- 2014-01-30 JP JP2014015276A patent/JP5985523B2/ja active Active
- 2014-06-09 HR HRP20140537AT patent/HRP20140537T1/hr unknown
- 2014-07-01 CY CY20141100489T patent/CY1115259T1/el unknown
-
2016
- 2016-03-30 JP JP2016066978A patent/JP6422460B2/ja active Active
- 2016-04-27 US US15/140,077 patent/US9636427B2/en active Active
- 2016-04-27 US US15/140,132 patent/US20160235868A1/en not_active Abandoned
- 2016-10-11 HR HRP20161312TT patent/HRP20161312T2/hr unknown
- 2016-11-03 CY CY20161101126T patent/CY1118985T1/el unknown
-
2017
- 2017-03-22 US US15/466,600 patent/US9907866B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2799090T3 (da) | Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering | |
US10918743B2 (en) | Contrast medium formulation and related preparation method | |
US20190269805A1 (en) | Solvent-free gadolinium contrast agents | |
US20180185521A1 (en) | Solvent-Free Gadolinium Contrast Agents | |
CN113164628A (zh) | 造影介质制剂及其制备方法 |